Abivax's latest disclosures mean its lead drug candidate has the most compelling dataset in ulcerative colitis at the moment, Stifel analysts say in a research note. New study results released this week by the French biotech company for its obefazimod experimental drug for ulcerative colitis should help settle a debate among investors about the medicine's malignancy risk, the analysts say. Moreover, obefazimod's efficacy was validated, with robust results even for hard-to-treat patients, they add. Stifel lifts its estimate on obefazimod's peak sales to 4 billion euros from 2.5 billion euros previously, and expects this to be achieved by 2032 or 2033. (adria.calatayud@wsj.com)